<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544595</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A2302E1</org_study_id>
    <secondary_id>2012-000533-39</secondary_id>
    <nct_id>NCT01544595</nct_id>
  </id_info>
  <brief_title>Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 4 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an extension study of secukinumab prefilled syringes in subjects with moderate to
      severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with
      secukinumab. Subjects on secukinumab at the end of treatment period in phase III studies
      (e.g., ongoing CAIN457A2302 and CAIN457A2303 and potentially other secukinumab phase III
      studies) were eligible to join this extension study. This extension study was planned to
      collect an additional 2 years of long-term efficacy, safety, and tolerability data of
      secukinumab in either continuous or interrupted therapy (randomized withdrawal period) in
      subjects showing at least partial response to secukinumab and completing treatment period on
      secukinumab in previous phase III studies. In this extension study, the prefilled syringe
      (PFS) liquid formulation of secukinumab were used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2012</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 26, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68</measure>
    <time_frame>At week 68 (16 weeks after week 52)</time_frame>
    <description>The primary variable was the cumulative rate of patients who lost PASI 75 response up to Week 68 (time=0 being defined as Week 52).
Loss of PASI 75 response was analyzed by means of a survival analysis defining &quot;loss of PASI 75 response&quot; as &quot;failure&quot;. The term cumulative rate corresponded to 1 minus the survival function within this survival analysis, and the cumulative rate and the survival functions were dependent on time t.
PASI 75 response: patients achieving ≥ 75% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 75 responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With PASI 50, PASI 75, PASI 90, PASI 100 and IGA Mod 2011 0 or 1 (Observed Data) - Randomized Withdrawal Period</measure>
    <time_frame>Week 52, 104, and 156</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) 75 responder at week 52. Patients in the placebo groups were not evaluable after re-treatment with Secukinumab.
PASI 75 Responders: patients with a PASI 75 response (patients achieving ≥75% improvement [reduction] in PASI score compared to baseline of the core study).
PASI 50 response: patients achieving ≥ 50% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 50 responders.
PASI 90 response: patients achieving ≥ 90% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 90 responders.
PASI 100 response/remission: complete clearing of psoriasis (PASI=0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With PASI 50, PASI 75, PASI 90, and PASI 100 (Observed Data) - Entire Study Period</measure>
    <time_frame>Week 52, Week 104, Week 156, week 208, week 260</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) scoring system: The average degree of severity of each sign in each of the four body regions was assigned a score of 0-4. The area covered by lesions on each body region was estimated as a percentage of the total area of that particular body region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline for PASI Score Over Time (Observed Data) - Randomized Withdrawal Period</measure>
    <time_frame>Week 52, 104, and 156</time_frame>
    <description>The improvement (decrease from baseline) in PASI total scores observed at Week 52.
Perc. change = 100 x Abs. change /Base. (Abs. change = Post - Base) For each post-baseline visit only patients with a value at both baseline and the respective post-baseline visit are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline for PASI Score Over Time (Observed Data) - Entire Study Period</measure>
    <time_frame>Week 52, Week 104, Week 156, week 208, week 260</time_frame>
    <description>Perc. change = 100 x Abs. change /Base. (Abs. change = Post - Base) For each post-baseline visit only patients with a value at both baseline and the respective post-baseline visit are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each IGA Mod 2011 Category (Observed Data)- Randomized Withdrawal Period</measure>
    <time_frame>Week 52 (baseline), 104, and 156</time_frame>
    <description>Investigator Global Assessment (IGA) mod 2011; scale from 0 - 4. Score 0: Clear (No signs of psoriasis. Post-inflammatory hyperpigmentation could be Present). Score 1: Almost clear (Normal to pink coloration of lesions; no thickening; no to minimal focal scaling), Score 2: Mild (Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling). Score 3: Moderate (Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling). Score 4: Severe (Bright to deep dark red coloration; severe thickening with hard edges; severe /coarse scaling covering almost all or all lesions).
Patients in the placebo groups were not evaluable after re-treatment with Secukinumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each IGA Mod 2011 Category (Observed Data) - Entire Study Period</measure>
    <time_frame>Week 52, Week 104, Week 156, week 208, week 260</time_frame>
    <description>Investigator's Global Assessment (IGA) mod 2011; scale from 0 - 4. Score 0= clear (no signs of psoriasis) Score 1 = almost clear no to minimal local scaling) Score 2 = mild (predominantly fine scaling) Score 3 = moderate (moderate scaling) Score 4 = severe (severe/coarse scaling covering almost all or all lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With IGA Mod 2011 0/1 Response (Observed Data) - Entire Study Period</measure>
    <time_frame>Week 52, Week 104, Week 156, week 208, week 260</time_frame>
    <description>Investigator's Global Assessment (IGA) mod 2011 0/1. Score 0= clear (no signs of psoriasis) Score 1 = almost clear no to minimal local scaling) Score 2 = mild (predominantly fine scaling) Score 3 = moderate (moderate scaling) Score 4 = severe (severe/coarse scaling covering almost all or all lesions) Based on this scale, a patient was considered as IGA mod 2011 0/1 responder if the patient achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Loss of IGA Mod 2011 0 or 1 Response Over Time for Subjects With IGA Mod 2011 0 or 1 Response at Week 52 - Randomized Withdrawal Period</measure>
    <time_frame>Week 68</time_frame>
    <description>Summary for loss of IGA mod 2011 0 or 1 response over time for patients with response at Week 52.
time = 0 refers to Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With PASI 75 Response - Treatment Period for Re-treated After Relapse</measure>
    <time_frame>up to week 260</time_frame>
    <description>PASI 75 response since reinitiating treatment after relapse. time = 0 refers to Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With IGA Mod 0 or 1 Response - Treatment Period for Re-treated After Relapse</measure>
    <time_frame>up to week 260</time_frame>
    <description>IGA mod 2011 0 or 1 response since reinitiating treatment after relapse for subjects with IGA 0 or 1 response at week 52 and not have IGA 0 or 1 response at relapse.
time = 0 refers to Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent pf Participants With Relapse Over Time - Randomized Withdrawal Period</measure>
    <time_frame>up to week 156</time_frame>
    <description>Time 0 = week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Relapse After Last Injection</measure>
    <time_frame>up to week 16</time_frame>
    <description>Relapse: when the achieved maximal PASI improvement from baseline of core study was reduced by &gt;50%.
Time 0 = week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Rebound After Last Injection</measure>
    <time_frame>up to week 68</time_frame>
    <description>Rebound: PASI increases to &gt; 125% of baseline (where baseline is the PASI at the randomization of the core study) or presence of new pustular psoriasis, new erythrodermic psoriasis or more inflammatory psoriasis occurring within 8 Weeks of stopping therapy (after the last dose of study treatment received). Rebound like event (RLE) was defined as increase of PASI of &gt; 125% from baseline value or occurrence of new pustular, new erythrodermic or more inflammatory psoriasis any time after stopping therapy (last treatment administered) up to Week 68. Rebound was evaluated for the patients randomized to the placebo groups in the extension study; hence these patients received the last dose of secukinumab during the core studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dermatology Life Quality Index Response (DLQI 0 or 1) - Randomized Withdrawal Period (Observed Data)</measure>
    <time_frame>Week 52 (baseline), 64, 76, 88, 104, 116, 128, 140, and 156</time_frame>
    <description>Dermatology Life Quality Index (DLQI) scores range from 0 to 30. Lower absolute scores on DLQI indicate better/improved health-related quality-of life impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dermatology Life Quality Index Response (DLQI 0 or 1) - Entire Treatment Period</measure>
    <time_frame>Week 52 (baseline), 64, 76, 88, 104, 116, 128, 140, and 156</time_frame>
    <description>Dermatology Life Quality Index (DLQI) scores range from 0 to 30. Lower absolute scores on DLQI indicate better/improved health-related quality-of life impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Health State Assessment (Observed Value) - Randomized Withdrawal Period</measure>
    <time_frame>Week 52 (baseline), 64, 76, 88, 104, 116, 128, 140, and 156</time_frame>
    <description>EQ-5D: EuroQOL 5-Dimension Health Status Questionnaire. The EQ-5D© is a generic instrument to assess each patient's health status. It provides a simple descriptive profile and a single index value for health status. The EQ visual analog scale records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Health State Assessment (Observed Value) - Entire Study Period</measure>
    <time_frame>week 64, 76, 88, 104, 116, 128, 140, and 156</time_frame>
    <description>EQ-5D: EuroQOL 5-Dimension Health Status Questionnaire. The EQ-5D© is a generic instrument to assess each patient's health status. It provides a simple descriptive profile and a single index value for health status. The EQ visual analog scale records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Evaluation - Hematology Parameters: Incidence Rate for Participants With Clinically CTCAE - Randomized Withdrawal Period</measure>
    <time_frame>Week 52-156</time_frame>
    <description>CTCAE: common terminology criteria for adverse events. A subject with multiple variable measurements is counted only once under the worst condition. LLN = lower limit of normal.
IR=incidence rate per 100 subject years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Evaluation: Number of Participants With Clinically CTCAE - Entire Study Period</measure>
    <time_frame>approximately 4 years</time_frame>
    <description>CTCAE: common terminology criteria for adverse events. A subject with multiple variable measurements is counted only once under the worst condition. LLN = lower limit of normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram: Incidence of Participants With ECG Test Results - Randomized Withdrawal Period</measure>
    <time_frame>Week 52 - 156</time_frame>
    <description>QTcB: QT interval corrected using Bazett's formula QTcF: QT interval corrected using Fridericia's formula A patient with multiple variable measurements is counted only once under the worst condition.
IR=incidence rate per 100 subject years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram: Number of Participants With ECG Test Results - Entire Treatment Period</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>QTcB: QT interval corrected using Bazett's formula QTcF: QT interval corrected using Fridericia's formula A patient with multiple variable measurements is counted only once under the worst condition.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1147</enrollment>
  <condition>Moderate to Severe Plaque-type Psoriasis</condition>
  <arm_group>
    <arm_group_label>PASI 75 Responders</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PASI 75 responders participated in &quot;randomized withdrawal&quot;. Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies were randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Participants on first full relapse received loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Partial responders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Partial responders were not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies did not participate in the randomized withdrawal. These subjects continued same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab (AIN457)</intervention_name>
    <description>Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a &quot;messenger&quot; protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions.</description>
    <arm_group_label>PASI 75 Responders</arm_group_label>
    <arm_group_label>Partial responders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>PASI 75 Responders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Completed the full study treatment period of 52 weeks in preceding phase III studies, and
        have been receiving secukinumab treatment during the maintenance phase of the preceding
        phase III studies, and show at least a partial response (PASI 50 or better) at Week 52 of
        the preceding phase III studies.

        Written informed consent form.

        Key Exclusion Criteria:

        A protocol deviation in either of the preceding phase III studies which according to the
        investigator prevented the meaningful analysis of the extension study for the individual
        subject.

        Ongoing use of prohibited psoriasis or non-psoriasis treatments.

        Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female
        after conception and until the termination of gestation, confirmed by a positive hCG
        laboratory test (&gt;10 mIU/mL).

        Women of child-bearing potential, defined as all women physiologically capable of becoming
        pregnant, unwilling to use effective contraception during the study and for 16 weeks after
        stopping treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warren</city>
        <state>Ohio</state>
        <zip>44483</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oregon City</city>
        <state>Oregon</state>
        <zip>97045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-1613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1062ABK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1122AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425BEI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425DKG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5502EZA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond Hil</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Cedex 10</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13913</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martigues</city>
        <zip>13500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reims</city>
        <zip>51090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osnabrueck</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plauen</city>
        <zip>08529</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuppertal</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kopavogur</city>
        <zip>201</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurume city</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi city</city>
        <state>Gunma</state>
        <zip>371 8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asahikawa-city</city>
        <state>Hokkaido</state>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-City</city>
        <state>Hyogo</state>
        <zip>654-0155</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Inashiki-gun</city>
        <state>Ibaraki</state>
        <zip>300-0395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Isehara-city</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>213-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sagamihara-city</city>
        <state>Kanagawa</state>
        <zip>228-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo ku</city>
        <state>Tokyo</state>
        <zip>113 8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>102-8798</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141 8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daejeon</city>
        <state>Korea</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <state>LVA</state>
        <zip>LV-5404</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ventspils</city>
        <state>LVA</state>
        <zip>LV-3601</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1012</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LTU</state>
        <zip>LT-50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <state>LTU</state>
        <zip>92304</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-07195</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60 529</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>041335</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Coloma De Gramanet</city>
        <state>Cataluña</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malmo</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hsin Chu</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yeovil</city>
        <state>Somerset</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dudley</city>
        <state>West Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harrogate</city>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nuneaton</city>
        <zip>CV10 7DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Iceland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Egypt</country>
    <country>India</country>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <results_first_submitted>June 25, 2018</results_first_submitted>
  <results_first_submitted_qc>November 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 20, 2018</results_first_posted>
  <last_update_submitted>November 27, 2018</last_update_submitted>
  <last_update_submitted_qc>November 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis, inflammatory skin disease</keyword>
  <keyword>scaly patches</keyword>
  <keyword>secukinumab (AIN457)</keyword>
  <keyword>Psoriasis Area and Severity Index (PASI)</keyword>
  <keyword>Investigator Global Assessment (IGA) mod 2011</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT01544595/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT01544595/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Among the 1146 patients who completed the screening phase, 995 “PASI 75 responder at week 52” patients were randomized in a double blind fashion to either active treatment or placebo &amp; entered the randomized withdrawal period and 151 “partial responders at week 52&quot; patients entered treatment period of the Extension.</recruitment_details>
      <pre_assignment_details>1366 patients who completed the core studies (CAIN457A2302 or CAIN457A2303) and provided consent for participation in the extension study were screened, and 1146 (83.9%) completed the screening phase and entered the extension.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AIN457 150 mg –Randomized Withdrawal Period</title>
          <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
        </group>
        <group group_id="P2">
          <title>AIN457 300 mg –Randomized Withdrawal Period</title>
          <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
        </group>
        <group group_id="P3">
          <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
          <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
        </group>
        <group group_id="P4">
          <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
          <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
        </group>
        <group group_id="P5">
          <title>AIN457 150 mg - Partial Responders</title>
          <description>PASI 50 responders / PASI 75 non responders at Week 52, treated with AIN 150 mg in core and extension study</description>
        </group>
        <group group_id="P6">
          <title>AIN457 300 mg - Partial Responders</title>
          <description>PASI 50 responders / PASI 75 non responders at Week 52, treated with AIN 300 mg in core and extension study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Status at Week 68</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="363"/>
                <participants group_id="P3" count="150"/>
                <participants group_id="P4" count="181"/>
                <participants group_id="P5" count="0">These patients were not in the study arms at this time point.</participants>
                <participants group_id="P6" count="0">These patients were not in the study arms at this time point.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="346"/>
                <participants group_id="P3" count="87"/>
                <participants group_id="P4" count="130"/>
                <participants group_id="P5" count="0">These patients were not in the study arms at this time point.</participants>
                <participants group_id="P6" count="0">These patients were not in the study arms at this time point.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved to treatment period ≤ wk 68</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Status at Week 156</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="363"/>
                <participants group_id="P3" count="150"/>
                <participants group_id="P4" count="181"/>
                <participants group_id="P5" count="98"/>
                <participants group_id="P6" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="285"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="140"/>
                <participants group_id="P4" count="166"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatement</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved to treatment period ≤ wk 156</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="131"/>
                <participants group_id="P4" count="145"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set was defined as all patients who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>AIN457 150 mg –Randomized Withdrawal Period</title>
          <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
        </group>
        <group group_id="B2">
          <title>AIN457 300 mg –Randomized Withdrawal Period</title>
          <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
        </group>
        <group group_id="B3">
          <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
          <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
        </group>
        <group group_id="B4">
          <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
          <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
        </group>
        <group group_id="B5">
          <title>AIN457 150 mg - Partial Responders</title>
          <description>PASI 50 responders / PASI 75 non responders at Week 52, treated with AIN 150 mg in core and extension study</description>
        </group>
        <group group_id="B6">
          <title>AIN457 300 mg - Partial Responders</title>
          <description>PASI 50 responders / PASI 75 non responders at Week 52, treated with AIN 300 mg in core and extension study</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="301"/>
            <count group_id="B2" value="363"/>
            <count group_id="B3" value="150"/>
            <count group_id="B4" value="181"/>
            <count group_id="B5" value="98"/>
            <count group_id="B6" value="53"/>
            <count group_id="B7" value="1146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="12.93"/>
                    <measurement group_id="B2" value="45.8" spread="12.92"/>
                    <measurement group_id="B3" value="47.1" spread="13.34"/>
                    <measurement group_id="B4" value="45.4" spread="13.09"/>
                    <measurement group_id="B5" value="46.8" spread="12.78"/>
                    <measurement group_id="B6" value="48.5" spread="11.98"/>
                    <measurement group_id="B7" value="46.2" spread="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="330"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="70"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="136"/>
                    <measurement group_id="B5" value="73"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68</title>
        <description>The primary variable was the cumulative rate of patients who lost PASI 75 response up to Week 68 (time=0 being defined as Week 52).
Loss of PASI 75 response was analyzed by means of a survival analysis defining &quot;loss of PASI 75 response&quot; as &quot;failure&quot;. The term cumulative rate corresponded to 1 minus the survival function within this survival analysis, and the cumulative rate and the survival functions were dependent on time t.
PASI 75 response: patients achieving ≥ 75% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 75 responders.</description>
        <time_frame>At week 68 (16 weeks after week 52)</time_frame>
        <population>Full analysis set (FAS): patients from randomized set with at least 1 post baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68</title>
          <description>The primary variable was the cumulative rate of patients who lost PASI 75 response up to Week 68 (time=0 being defined as Week 52).
Loss of PASI 75 response was analyzed by means of a survival analysis defining &quot;loss of PASI 75 response&quot; as &quot;failure&quot;. The term cumulative rate corresponded to 1 minus the survival function within this survival analysis, and the cumulative rate and the survival functions were dependent on time t.
PASI 75 response: patients achieving ≥ 75% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 75 responders.</description>
          <population>Full analysis set (FAS): patients from randomized set with at least 1 post baseline efficacy assessment.</population>
          <units>Cummulative rate</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" lower_limit="25.8" upper_limit="79.7"/>
                    <measurement group_id="O2" value="25.4" lower_limit="9.8" upper_limit="56.5"/>
                    <measurement group_id="O3" value="74.3" lower_limit="56.9" upper_limit="88.8"/>
                    <measurement group_id="O4" value="64.7" lower_limit="52.0" upper_limit="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for 52 weeks≤ t ≤68 weeks
H1: p1(t) – p0,1(t) = 0 versus HA1: p1(t)– p0,1(t) ≥ 0,
H2: p2(t) – p0,2(t) = 0 versus HA2: p2(t) – p0,2(t) ≥ 0,</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>H1: Secukinumab 150 mg was not different from placebo with respect to the cumulative rate for patients who lost PASI 75 response up to Week 68
• H2: Secukinumab 300 mg was not different from placebo with respect to the cumulative rate for patients who lost PASI 75 response up to Week 68</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for 52 weeks≤ t ≤68 weeks
H1: p1(t) – p0,1(t) = 0 versus HA1: p1(t)– p0,1(t) ≥ 0,
H2: p2(t) – p0,2(t) = 0 versus HA2: p2(t) – p0,2(t) ≥ 0,</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>H1: Secukinumab 150 mg was not different from placebo with respect to the cumulative rate for patients who lost PASI 75 response up to Week 68
• H2: Secukinumab 300 mg was not different from placebo with respect to the cumulative rate for patients who lost PASI 75 response up to Week 68</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With PASI 50, PASI 75, PASI 90, PASI 100 and IGA Mod 2011 0 or 1 (Observed Data) - Randomized Withdrawal Period</title>
        <description>Psoriasis Area and Severity Index (PASI) 75 responder at week 52. Patients in the placebo groups were not evaluable after re-treatment with Secukinumab.
PASI 75 Responders: patients with a PASI 75 response (patients achieving ≥75% improvement [reduction] in PASI score compared to baseline of the core study).
PASI 50 response: patients achieving ≥ 50% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 50 responders.
PASI 90 response: patients achieving ≥ 90% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 90 responders.
PASI 100 response/remission: complete clearing of psoriasis (PASI=0)</description>
        <time_frame>Week 52, 104, and 156</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PASI 50, PASI 75, PASI 90, PASI 100 and IGA Mod 2011 0 or 1 (Observed Data) - Randomized Withdrawal Period</title>
          <description>Psoriasis Area and Severity Index (PASI) 75 responder at week 52. Patients in the placebo groups were not evaluable after re-treatment with Secukinumab.
PASI 75 Responders: patients with a PASI 75 response (patients achieving ≥75% improvement [reduction] in PASI score compared to baseline of the core study).
PASI 50 response: patients achieving ≥ 50% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 50 responders.
PASI 90 response: patients achieving ≥ 90% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 90 responders.
PASI 100 response/remission: complete clearing of psoriasis (PASI=0)</description>
          <population>FAS</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 52 - IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="309"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="363"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296"/>
                    <measurement group_id="O2" value="361"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="303"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="191"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254"/>
                    <measurement group_id="O2" value="329"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="299"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="240"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="202"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="322"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="287"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - PASI 90 (n=239, 324, 10,15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="207"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With PASI 50, PASI 75, PASI 90, and PASI 100 (Observed Data) - Entire Study Period</title>
        <description>Psoriasis Area and Severity Index (PASI) scoring system: The average degree of severity of each sign in each of the four body regions was assigned a score of 0-4. The area covered by lesions on each body region was estimated as a percentage of the total area of that particular body region.</description>
        <time_frame>Week 52, Week 104, Week 156, week 208, week 260</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg Only</title>
            <description>patients staying strictly on AIN457 150mg from Week 52</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg Only</title>
            <description>Patients staying strictly on AIN457 300mg from Week 52</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PASI 50, PASI 75, PASI 90, and PASI 100 (Observed Data) - Entire Study Period</title>
          <description>Psoriasis Area and Severity Index (PASI) scoring system: The average degree of severity of each sign in each of the four body regions was assigned a score of 0-4. The area covered by lesions on each body region was estimated as a percentage of the total area of that particular body region.</description>
          <population>FAS</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 52 - PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - PASI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208 - PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208 - PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208 - PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208 - PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260 - PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260 - PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260 - PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260 - PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline for PASI Score Over Time (Observed Data) - Randomized Withdrawal Period</title>
        <description>The improvement (decrease from baseline) in PASI total scores observed at Week 52.
Perc. change = 100 x Abs. change /Base. (Abs. change = Post - Base) For each post-baseline visit only patients with a value at both baseline and the respective post-baseline visit are included.</description>
        <time_frame>Week 52, 104, and 156</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline for PASI Score Over Time (Observed Data) - Randomized Withdrawal Period</title>
          <description>The improvement (decrease from baseline) in PASI total scores observed at Week 52.
Perc. change = 100 x Abs. change /Base. (Abs. change = Post - Base) For each post-baseline visit only patients with a value at both baseline and the respective post-baseline visit are included.</description>
          <population>FAS</population>
          <units>Percent change in PASI score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 (baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.31" spread="7.878"/>
                    <measurement group_id="O2" value="-95.98" spread="6.638"/>
                    <measurement group_id="O3" value="-92.88" spread="8.435"/>
                    <measurement group_id="O4" value="-96.16" spread="6.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.88" spread="14.631"/>
                    <measurement group_id="O2" value="-91.51" spread="13.221"/>
                    <measurement group_id="O3" value="-82.67" spread="15.568"/>
                    <measurement group_id="O4" value="-78.04" spread="20.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.32" spread="17.341"/>
                    <measurement group_id="O2" value="-90.50" spread="11.660"/>
                    <measurement group_id="O3" value="-79.77" spread="15.172"/>
                    <measurement group_id="O4" value="-86.35" spread="15.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline for PASI Score Over Time (Observed Data) - Entire Study Period</title>
        <description>Perc. change = 100 x Abs. change /Base. (Abs. change = Post - Base) For each post-baseline visit only patients with a value at both baseline and the respective post-baseline visit are included.</description>
        <time_frame>Week 52, Week 104, Week 156, week 208, week 260</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg Only</title>
            <description>patients staying strictly on AIN457 150mg from Week 52</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg Only</title>
            <description>Patients staying strictly on AIN457 300mg from Week 52</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline for PASI Score Over Time (Observed Data) - Entire Study Period</title>
          <description>Perc. change = 100 x Abs. change /Base. (Abs. change = Post - Base) For each post-baseline visit only patients with a value at both baseline and the respective post-baseline visit are included.</description>
          <population>FAS</population>
          <units>Percent change in PASI score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.93" spread="14.815"/>
                    <measurement group_id="O2" value="-91.82" spread="11.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.97" spread="18.811"/>
                    <measurement group_id="O2" value="-88.86" spread="16.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-93.03" spread="12.338"/>
                    <measurement group_id="O2" value="-87.78" spread="15.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-95.71" spread="7.868"/>
                    <measurement group_id="O2" value="-88.25" spread="14.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-93.65" spread="9.959"/>
                    <measurement group_id="O2" value="-88.08" spread="14.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each IGA Mod 2011 Category (Observed Data)- Randomized Withdrawal Period</title>
        <description>Investigator Global Assessment (IGA) mod 2011; scale from 0 - 4. Score 0: Clear (No signs of psoriasis. Post-inflammatory hyperpigmentation could be Present). Score 1: Almost clear (Normal to pink coloration of lesions; no thickening; no to minimal focal scaling), Score 2: Mild (Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling). Score 3: Moderate (Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling). Score 4: Severe (Bright to deep dark red coloration; severe thickening with hard edges; severe /coarse scaling covering almost all or all lesions).
Patients in the placebo groups were not evaluable after re-treatment with Secukinumab</description>
        <time_frame>Week 52 (baseline), 104, and 156</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each IGA Mod 2011 Category (Observed Data)- Randomized Withdrawal Period</title>
          <description>Investigator Global Assessment (IGA) mod 2011; scale from 0 - 4. Score 0: Clear (No signs of psoriasis. Post-inflammatory hyperpigmentation could be Present). Score 1: Almost clear (Normal to pink coloration of lesions; no thickening; no to minimal focal scaling), Score 2: Mild (Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling). Score 3: Moderate (Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling). Score 4: Severe (Bright to deep dark red coloration; severe thickening with hard edges; severe /coarse scaling covering almost all or all lesions).
Patients in the placebo groups were not evaluable after re-treatment with Secukinumab</description>
          <population>FAS</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 52 - clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - almost clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - almost clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - almost clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each IGA Mod 2011 Category (Observed Data) - Entire Study Period</title>
        <description>Investigator's Global Assessment (IGA) mod 2011; scale from 0 - 4. Score 0= clear (no signs of psoriasis) Score 1 = almost clear no to minimal local scaling) Score 2 = mild (predominantly fine scaling) Score 3 = moderate (moderate scaling) Score 4 = severe (severe/coarse scaling covering almost all or all lesions)</description>
        <time_frame>Week 52, Week 104, Week 156, week 208, week 260</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg Only</title>
            <description>patients staying strictly on AIN457 150mg from Week 52</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg Only</title>
            <description>Patients staying strictly on AIN457 300mg from Week 52</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each IGA Mod 2011 Category (Observed Data) - Entire Study Period</title>
          <description>Investigator's Global Assessment (IGA) mod 2011; scale from 0 - 4. Score 0= clear (no signs of psoriasis) Score 1 = almost clear no to minimal local scaling) Score 2 = mild (predominantly fine scaling) Score 3 = moderate (moderate scaling) Score 4 = severe (severe/coarse scaling covering almost all or all lesions)</description>
          <population>FAS</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 52 - clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - almost clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 52 - severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - almost clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104 - severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - almost clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156 - severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208 - clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208 - almost clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208 - mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208 - moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208 - severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260 - clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260 - almost clear</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260 - mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260 - moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260 - severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With IGA Mod 2011 0/1 Response (Observed Data) - Entire Study Period</title>
        <description>Investigator's Global Assessment (IGA) mod 2011 0/1. Score 0= clear (no signs of psoriasis) Score 1 = almost clear no to minimal local scaling) Score 2 = mild (predominantly fine scaling) Score 3 = moderate (moderate scaling) Score 4 = severe (severe/coarse scaling covering almost all or all lesions) Based on this scale, a patient was considered as IGA mod 2011 0/1 responder if the patient achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline.</description>
        <time_frame>Week 52, Week 104, Week 156, week 208, week 260</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg Only</title>
            <description>patients staying strictly on AIN457 150mg from Week 52</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg Only</title>
            <description>Patients staying strictly on AIN457 300mg from Week 52</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With IGA Mod 2011 0/1 Response (Observed Data) - Entire Study Period</title>
          <description>Investigator's Global Assessment (IGA) mod 2011 0/1. Score 0= clear (no signs of psoriasis) Score 1 = almost clear no to minimal local scaling) Score 2 = mild (predominantly fine scaling) Score 3 = moderate (moderate scaling) Score 4 = severe (severe/coarse scaling covering almost all or all lesions) Based on this scale, a patient was considered as IGA mod 2011 0/1 responder if the patient achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline.</description>
          <population>FAS</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Loss of IGA Mod 2011 0 or 1 Response Over Time for Subjects With IGA Mod 2011 0 or 1 Response at Week 52 - Randomized Withdrawal Period</title>
        <description>Summary for loss of IGA mod 2011 0 or 1 response over time for patients with response at Week 52.
time = 0 refers to Week 52</description>
        <time_frame>Week 68</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Loss of IGA Mod 2011 0 or 1 Response Over Time for Subjects With IGA Mod 2011 0 or 1 Response at Week 52 - Randomized Withdrawal Period</title>
          <description>Summary for loss of IGA mod 2011 0 or 1 response over time for patients with response at Week 52.
time = 0 refers to Week 52</description>
          <population>FAS</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="29.8" upper_limit="47.7"/>
                    <measurement group_id="O2" value="33.4" lower_limit="25.7" upper_limit="42.6"/>
                    <measurement group_id="O3" value="82.1" lower_limit="71.2" upper_limit="90.8"/>
                    <measurement group_id="O4" value="65.5" lower_limit="53.8" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With PASI 75 Response - Treatment Period for Re-treated After Relapse</title>
        <description>PASI 75 response since reinitiating treatment after relapse. time = 0 refers to Week 52</description>
        <time_frame>up to week 260</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - AIN457 150 mg</title>
            <description>Patients randomized to placebo at Week 52, treated with AIN457 150mg after they relapsed</description>
          </group>
          <group group_id="O2">
            <title>Placebo - AIN457 300 mg</title>
            <description>Patients randomized to placebo at Week 52, treated with AIN457 300mg after they relapsed</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With PASI 75 Response - Treatment Period for Re-treated After Relapse</title>
          <description>PASI 75 response since reinitiating treatment after relapse. time = 0 refers to Week 52</description>
          <population>FAS</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to &lt;=4 wks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="30.7" upper_limit="47.4"/>
                    <measurement group_id="O2" value="51.0" lower_limit="43.2" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;12 to &lt;=16 wks (n=21,13)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="85.5" upper_limit="95.3"/>
                    <measurement group_id="O2" value="95.1" lower_limit="90.7" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;80 to &lt;=84 wks (n=2,1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="92.6" upper_limit="98.9"/>
                    <measurement group_id="O2" value="98.8" lower_limit="94.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With IGA Mod 0 or 1 Response - Treatment Period for Re-treated After Relapse</title>
        <description>IGA mod 2011 0 or 1 response since reinitiating treatment after relapse for subjects with IGA 0 or 1 response at week 52 and not have IGA 0 or 1 response at relapse.
time = 0 refers to Week 52</description>
        <time_frame>up to week 260</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - AIN457 150 mg</title>
            <description>Patients randomized to placebo at Week 52, treated with AIN457 150mg after they relapsed</description>
          </group>
          <group group_id="O2">
            <title>Placebo - AIN457 300 mg</title>
            <description>Patients randomized to placebo at Week 52, treated with AIN457 300mg after they relapsed</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With IGA Mod 0 or 1 Response - Treatment Period for Re-treated After Relapse</title>
          <description>IGA mod 2011 0 or 1 response since reinitiating treatment after relapse for subjects with IGA 0 or 1 response at week 52 and not have IGA 0 or 1 response at relapse.
time = 0 refers to Week 52</description>
          <population>FAS</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to &lt;=4 wks (n=96,123)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="7.3" upper_limit="21.0"/>
                    <measurement group_id="O2" value="28.1" lower_limit="21.0" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;12 to &lt;=16 wks (n=40,32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="66.0" upper_limit="83.1"/>
                    <measurement group_id="O2" value="83.5" lower_limit="76.3" upper_limit="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;84 to &lt;=88 wks (n=7,4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9" lower_limit="80.0" upper_limit="93.8"/>
                    <measurement group_id="O2" value="90.8" lower_limit="84.5" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent pf Participants With Relapse Over Time - Randomized Withdrawal Period</title>
        <description>Time 0 = week 52</description>
        <time_frame>up to week 156</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent pf Participants With Relapse Over Time - Randomized Withdrawal Period</title>
          <description>Time 0 = week 52</description>
          <population>FAS</population>
          <units>Percent of participants with relapses</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to &lt;=4 wks (n=286,353,150,180)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="353"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;12 to &lt;=16 wks (n=297,363,124,160)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="363"/>
                    <count group_id="O3" value="124"/>
                    <count group_id="O4" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.6" upper_limit="5.9"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.1" upper_limit="4.4"/>
                    <measurement group_id="O3" value="19.8" lower_limit="13.9" upper_limit="27.7"/>
                    <measurement group_id="O4" value="12.1" lower_limit="8.0" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;92 to &lt;=96 wks (n=188,292,11,15)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="16.9" upper_limit="27.0"/>
                    <measurement group_id="O2" value="9.4" lower_limit="6.8" upper_limit="13.1"/>
                    <measurement group_id="O3" value="88.1" lower_limit="80.9" upper_limit="93.5"/>
                    <measurement group_id="O4" value="86.1" lower_limit="79.6" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;104 to &lt;=108 wks (n=156,297,8,9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="297"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="17.3" upper_limit="27.5"/>
                    <measurement group_id="O2" value="9.4" lower_limit="6.8" upper_limit="13.1"/>
                    <measurement group_id="O3" value="88.1" lower_limit="80.9" upper_limit="93.5"/>
                    <measurement group_id="O4" value="86.1" lower_limit="79.6" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Relapse After Last Injection</title>
        <description>Relapse: when the achieved maximal PASI improvement from baseline of core study was reduced by &gt;50%.
Time 0 = week 52</description>
        <time_frame>up to week 16</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg Only</title>
            <description>patients staying strictly on AIN457 150mg from Week 52</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg Only</title>
            <description>Patients staying strictly on AIN457 300mg from Week 52</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Relapse After Last Injection</title>
          <description>Relapse: when the achieved maximal PASI improvement from baseline of core study was reduced by &gt;50%.
Time 0 = week 52</description>
          <population>FAS</population>
          <units>Percent of participants with relapse</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to &lt;=4 wks (n=158,415)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="4.0" upper_limit="12.6"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;12 to &lt;=16 wks (n=66,208)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" lower_limit="22.6" upper_limit="48.9"/>
                    <measurement group_id="O2" value="28.4" lower_limit="21.8" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Rebound After Last Injection</title>
        <description>Rebound: PASI increases to &gt; 125% of baseline (where baseline is the PASI at the randomization of the core study) or presence of new pustular psoriasis, new erythrodermic psoriasis or more inflammatory psoriasis occurring within 8 Weeks of stopping therapy (after the last dose of study treatment received). Rebound like event (RLE) was defined as increase of PASI of &gt; 125% from baseline value or occurrence of new pustular, new erythrodermic or more inflammatory psoriasis any time after stopping therapy (last treatment administered) up to Week 68. Rebound was evaluated for the patients randomized to the placebo groups in the extension study; hence these patients received the last dose of secukinumab during the core studies.</description>
        <time_frame>up to week 68</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg Only</title>
            <description>patients staying strictly on AIN457 150mg from Week 52</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg Only</title>
            <description>Patients staying strictly on AIN457 300mg from Week 52</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Rebound After Last Injection</title>
          <description>Rebound: PASI increases to &gt; 125% of baseline (where baseline is the PASI at the randomization of the core study) or presence of new pustular psoriasis, new erythrodermic psoriasis or more inflammatory psoriasis occurring within 8 Weeks of stopping therapy (after the last dose of study treatment received). Rebound like event (RLE) was defined as increase of PASI of &gt; 125% from baseline value or occurrence of new pustular, new erythrodermic or more inflammatory psoriasis any time after stopping therapy (last treatment administered) up to Week 68. Rebound was evaluated for the patients randomized to the placebo groups in the extension study; hence these patients received the last dose of secukinumab during the core studies.</description>
          <population>FAS</population>
          <units>Percent of participants with rebound</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rebound (&lt;8 wks after last inj.; n=108,320)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="4.1" upper_limit="15.6"/>
                    <measurement group_id="O2" value="6.6" lower_limit="4.2" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RLE (&lt; 12 wks after last inj., n=110,326)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="6.7" upper_limit="19.7"/>
                    <measurement group_id="O2" value="9.5" lower_limit="6.7" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dermatology Life Quality Index Response (DLQI 0 or 1) - Randomized Withdrawal Period (Observed Data)</title>
        <description>Dermatology Life Quality Index (DLQI) scores range from 0 to 30. Lower absolute scores on DLQI indicate better/improved health-related quality-of life impairment.</description>
        <time_frame>Week 52 (baseline), 64, 76, 88, 104, 116, 128, 140, and 156</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dermatology Life Quality Index Response (DLQI 0 or 1) - Randomized Withdrawal Period (Observed Data)</title>
          <description>Dermatology Life Quality Index (DLQI) scores range from 0 to 30. Lower absolute scores on DLQI indicate better/improved health-related quality-of life impairment.</description>
          <population>FAS</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="359"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 (baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="295"/>
                    <count group_id="O2" value="359"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="281"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="357"/>
                    <count group_id="O3" value="126"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="265"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="284"/>
                    <count group_id="O2" value="352"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="256"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="346"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="247"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="262"/>
                    <count group_id="O2" value="337"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="237"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="326"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="230"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="326"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="222"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="241"/>
                    <count group_id="O2" value="327"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="229"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="215"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dermatology Life Quality Index Response (DLQI 0 or 1) - Entire Treatment Period</title>
        <description>Dermatology Life Quality Index (DLQI) scores range from 0 to 30. Lower absolute scores on DLQI indicate better/improved health-related quality-of life impairment.</description>
        <time_frame>Week 52 (baseline), 64, 76, 88, 104, 116, 128, 140, and 156</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg Only</title>
            <description>patients staying strictly on AIN457 150mg from Week 52</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg Only</title>
            <description>Patients staying strictly on AIN457 300mg from Week 52</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dermatology Life Quality Index Response (DLQI 0 or 1) - Entire Treatment Period</title>
          <description>Dermatology Life Quality Index (DLQI) scores range from 0 to 30. Lower absolute scores on DLQI indicate better/improved health-related quality-of life impairment.</description>
          <population>FAS</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 (baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="412"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="286"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D Health State Assessment (Observed Value) - Randomized Withdrawal Period</title>
        <description>EQ-5D: EuroQOL 5-Dimension Health Status Questionnaire. The EQ-5D© is a generic instrument to assess each patient's health status. It provides a simple descriptive profile and a single index value for health status. The EQ visual analog scale records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.</description>
        <time_frame>Week 52 (baseline), 64, 76, 88, 104, 116, 128, 140, and 156</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D Health State Assessment (Observed Value) - Randomized Withdrawal Period</title>
          <description>EQ-5D: EuroQOL 5-Dimension Health Status Questionnaire. The EQ-5D© is a generic instrument to assess each patient's health status. It provides a simple descriptive profile and a single index value for health status. The EQ visual analog scale records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.</description>
          <population>FAS</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="348"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="21.603"/>
                    <measurement group_id="O2" value="2.09" spread="28.358"/>
                    <measurement group_id="O3" value="-9.58" spread="20.339"/>
                    <measurement group_id="O4" value="-5.57" spread="27.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="337"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="25.605"/>
                    <measurement group_id="O2" value="2.76" spread="29.715"/>
                    <measurement group_id="O3" value="-13.73" spread="23.295"/>
                    <measurement group_id="O4" value="-9.27" spread="35.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="241"/>
                    <count group_id="O2" value="323"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="21.421"/>
                    <measurement group_id="O2" value="2.15" spread="29.702"/>
                    <measurement group_id="O3" value="-10.24" spread="26.026"/>
                    <measurement group_id="O4" value="-14.67" spread="27.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="310"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="24.075"/>
                    <measurement group_id="O2" value="1.57" spread="23.941"/>
                    <measurement group_id="O3" value="-2.81" spread="27.303"/>
                    <measurement group_id="O4" value="-9.65" spread="17.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="295"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="31.724"/>
                    <measurement group_id="O2" value="2.06" spread="24.814"/>
                    <measurement group_id="O3" value="-4.82" spread="20.921"/>
                    <measurement group_id="O4" value="-3.44" spread="11.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="33.078"/>
                    <measurement group_id="O2" value="3.17" spread="29.615"/>
                    <measurement group_id="O3" value="-5.59" spread="21.756"/>
                    <measurement group_id="O4" value="-5.97" spread="13.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="288"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="25.801"/>
                    <measurement group_id="O2" value="0.71" spread="18.151"/>
                    <measurement group_id="O3" value="-5.90" spread="27.335"/>
                    <measurement group_id="O4" value="-8.86" spread="18.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="284"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="34.259"/>
                    <measurement group_id="O2" value="2.23" spread="22.581"/>
                    <measurement group_id="O3" value="3.68" spread="26.836"/>
                    <measurement group_id="O4" value="-7.60" spread="20.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D Health State Assessment (Observed Value) - Entire Study Period</title>
        <description>EQ-5D: EuroQOL 5-Dimension Health Status Questionnaire. The EQ-5D© is a generic instrument to assess each patient's health status. It provides a simple descriptive profile and a single index value for health status. The EQ visual analog scale records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.</description>
        <time_frame>week 64, 76, 88, 104, 116, 128, 140, and 156</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg Only</title>
            <description>patients staying strictly on AIN457 150mg from Week 52</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg Only</title>
            <description>Patients staying strictly on AIN457 300mg from Week 52</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D Health State Assessment (Observed Value) - Entire Study Period</title>
          <description>EQ-5D: EuroQOL 5-Dimension Health Status Questionnaire. The EQ-5D© is a generic instrument to assess each patient's health status. It provides a simple descriptive profile and a single index value for health status. The EQ visual analog scale records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.</description>
          <population>FAS</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="22.506"/>
                    <measurement group_id="O2" value="1.44" spread="26.815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="398"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="22.339"/>
                    <measurement group_id="O2" value="2.10" spread="28.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 88</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="24.558"/>
                    <measurement group_id="O2" value="1.45" spread="28.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="376"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.15" spread="27.823"/>
                    <measurement group_id="O2" value="0.65" spread="23.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="21.022"/>
                    <measurement group_id="O2" value="1.21" spread="23.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" spread="23.584"/>
                    <measurement group_id="O2" value="1.93" spread="27.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="367"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="20.814"/>
                    <measurement group_id="O2" value="-0.44" spread="18.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="32.326"/>
                    <measurement group_id="O2" value="1.19" spread="21.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Evaluation - Hematology Parameters: Incidence Rate for Participants With Clinically CTCAE - Randomized Withdrawal Period</title>
        <description>CTCAE: common terminology criteria for adverse events. A subject with multiple variable measurements is counted only once under the worst condition. LLN = lower limit of normal.
IR=incidence rate per 100 subject years</description>
        <time_frame>Week 52-156</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Evaluation - Hematology Parameters: Incidence Rate for Participants With Clinically CTCAE - Randomized Withdrawal Period</title>
          <description>CTCAE: common terminology criteria for adverse events. A subject with multiple variable measurements is counted only once under the worst condition. LLN = lower limit of normal.
IR=incidence rate per 100 subject years</description>
          <population>Safety set</population>
          <units>IR</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes (&lt; LLN - 3.0 x 10E9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="4.7" upper_limit="10.1"/>
                    <measurement group_id="O2" value="4.9" lower_limit="3.3" upper_limit="7.0"/>
                    <measurement group_id="O3" value="7.2" lower_limit="2.6" upper_limit="15.6"/>
                    <measurement group_id="O4" value="8.6" lower_limit="4.1" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (&lt; 3.0 - 2.0 x 10E9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.3" upper_limit="1.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (&lt; 2.0 - 1.0 x 10E9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (&lt; 1.0 x 10E9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (&lt;LLN-0.8x10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="4.2" upper_limit="9.4"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.3" upper_limit="8.5"/>
                    <measurement group_id="O3" value="4.9" lower_limit="1.3" upper_limit="12.6"/>
                    <measurement group_id="O4" value="6.0" lower_limit="2.4" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (&lt;0.8-0.5x10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.6" upper_limit="5.2"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.9" upper_limit="3.2"/>
                    <measurement group_id="O3" value="6.3" lower_limit="2.1" upper_limit="14.7"/>
                    <measurement group_id="O4" value="3.4" lower_limit="0.9" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (&lt;0.5-0.2 x 10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (&lt;0.2x10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (&lt;LLN-1.5x10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="3.8" upper_limit="8.7"/>
                    <measurement group_id="O2" value="5.6" lower_limit="3.8" upper_limit="7.8"/>
                    <measurement group_id="O3" value="8.7" lower_limit="3.5" upper_limit="18.0"/>
                    <measurement group_id="O4" value="11.3" lower_limit="6.0" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (&lt;1.5-1.0x10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.9" upper_limit="3.2"/>
                    <measurement group_id="O3" value="2.4" lower_limit="0.3" upper_limit="8.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (&lt;1.0 - 0.5x10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.3" upper_limit="2.4"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="1.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (&lt;0.5x10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (LLN-75 x10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="1.8" upper_limit="5.5"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.9" upper_limit="4.9"/>
                    <measurement group_id="O3" value="2.4" lower_limit="0.3" upper_limit="8.6"/>
                    <measurement group_id="O4" value="5.4" lower_limit="2.0" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (&lt;75-50 x 10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (&lt;50-25 x 10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (&lt;25x10e9 /L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Evaluation: Number of Participants With Clinically CTCAE - Entire Study Period</title>
        <description>CTCAE: common terminology criteria for adverse events. A subject with multiple variable measurements is counted only once under the worst condition. LLN = lower limit of normal.</description>
        <time_frame>approximately 4 years</time_frame>
        <population>Safety set: The safety set included all patients who took at least one dose of study treatment during the treatment period. Patients were be analyzed according to treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Any AIN457 150 mg</title>
            <description>Safety data from patients while on AIN457 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Any AIN457 300 mg</title>
            <description>Safety data from patients while on AIN457 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Any AIN457</title>
            <description>safety data from patients while on any dose of AIN457</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Evaluation: Number of Participants With Clinically CTCAE - Entire Study Period</title>
          <description>CTCAE: common terminology criteria for adverse events. A subject with multiple variable measurements is counted only once under the worst condition. LLN = lower limit of normal.</description>
          <population>Safety set: The safety set included all patients who took at least one dose of study treatment during the treatment period. Patients were be analyzed according to treatment received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="890"/>
                <count group_id="O3" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes (&lt;LLN-3.0x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="832"/>
                    <count group_id="O3" value="1037"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (&lt;3.0-2.0 x 10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="866"/>
                    <count group_id="O3" value="1080"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (&lt;2.0-1.0x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="1085"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (&lt;1.0x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="870"/>
                    <count group_id="O3" value="1085"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (&lt;LLN-0.8x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="840"/>
                    <count group_id="O3" value="1041"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (&lt;0.8-0.5x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="861"/>
                    <count group_id="O3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (&lt;0.5-0.2 x 10e9 /L, n=545,864,1075)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="864"/>
                    <count group_id="O3" value="1075"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (&lt;0.2x10e9 /L, n=545,864,1075)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="864"/>
                    <count group_id="O3" value="1075"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (&lt;LLN-1.5x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="831"/>
                    <count group_id="O3" value="1037"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (&lt;1.5-1.0x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="861"/>
                    <count group_id="O3" value="1071"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (&lt;1.0 - 0.5x10e9 /L,)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="863"/>
                    <count group_id="O3" value="1074"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (&lt;0.5x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="864"/>
                    <count group_id="O3" value="1075"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (LLN-75x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="836"/>
                    <count group_id="O3" value="1042"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (&lt;75-50x10e9 /L,)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="862"/>
                    <count group_id="O3" value="1074"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (&lt;50-25 x 10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="862"/>
                    <count group_id="O3" value="1074"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (&lt;25x10e9 /L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="862"/>
                    <count group_id="O3" value="1074"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrocardiogram: Incidence of Participants With ECG Test Results - Randomized Withdrawal Period</title>
        <description>QTcB: QT interval corrected using Bazett's formula QTcF: QT interval corrected using Fridericia's formula A patient with multiple variable measurements is counted only once under the worst condition.
IR=incidence rate per 100 subject years.</description>
        <time_frame>Week 52 - 156</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to AIN150 mg</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg –Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to AIN300 mg</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 150 mg in core study and randomized to placebo</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg Placebo - Randomized Withdrawal Period</title>
            <description>PASI 75 responders at Week 52, treated with AIN 300 mg in core study and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram: Incidence of Participants With ECG Test Results - Randomized Withdrawal Period</title>
          <description>QTcB: QT interval corrected using Bazett's formula QTcF: QT interval corrected using Fridericia's formula A patient with multiple variable measurements is counted only once under the worst condition.
IR=incidence rate per 100 subject years.</description>
          <population>Safety set</population>
          <units>IR</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcB&gt;450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="7.5" upper_limit="14.3"/>
                    <measurement group_id="O2" value="9.4" lower_limit="7.0" upper_limit="12.4"/>
                    <measurement group_id="O3" value="11.3" lower_limit="4.9" upper_limit="22.3"/>
                    <measurement group_id="O4" value="14.1" lower_limit="7.5" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB&gt;480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.1" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.5" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB&gt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB change from baseline&gt;30 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="11.9" upper_limit="20.1"/>
                    <measurement group_id="O2" value="14.3" lower_limit="11.4" upper_limit="17.9"/>
                    <measurement group_id="O3" value="21.6" lower_limit="12.3" upper_limit="35.0"/>
                    <measurement group_id="O4" value="15.7" lower_limit="9.0" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB change from baseline&gt;60 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.1" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.3" upper_limit="1.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF&gt;450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.8" upper_limit="4.7"/>
                    <measurement group_id="O3" value="2.6" lower_limit="0.3" upper_limit="9.5"/>
                    <measurement group_id="O4" value="4.7" lower_limit="1.5" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF&gt;480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.1" upper_limit="1.7"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF&gt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF change from baseline&gt;30 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.6" upper_limit="9.9"/>
                    <measurement group_id="O2" value="6.8" lower_limit="4.8" upper_limit="9.2"/>
                    <measurement group_id="O3" value="7.9" lower_limit="2.9" upper_limit="17.2"/>
                    <measurement group_id="O4" value="9.5" lower_limit="4.6" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF change from baseline&gt;60 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.7"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR&gt;250 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrocardiogram: Number of Participants With ECG Test Results - Entire Treatment Period</title>
        <description>QTcB: QT interval corrected using Bazett's formula QTcF: QT interval corrected using Fridericia's formula A patient with multiple variable measurements is counted only once under the worst condition.</description>
        <time_frame>Approximately 4 years</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Any AIN457 150 mg</title>
            <description>Safety data from patients while on AIN457 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Any AIN457 300 mg</title>
            <description>Safety data from patients while on AIN457 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Any AIN457</title>
            <description>safety data from patients while on any dose of AIN457</description>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram: Number of Participants With ECG Test Results - Entire Treatment Period</title>
          <description>QTcB: QT interval corrected using Bazett's formula QTcF: QT interval corrected using Fridericia's formula A patient with multiple variable measurements is counted only once under the worst condition.</description>
          <population>Safety set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="890"/>
                <count group_id="O3" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcB&gt;500 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="851"/>
                    <count group_id="O3" value="1060"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB&gt;480 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="848"/>
                    <count group_id="O3" value="1056"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB&gt;450 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="804"/>
                    <count group_id="O3" value="1004"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB changes from baseline&gt;30 ms</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="851"/>
                    <count group_id="O3" value="1060"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="223"/>
                    <measurement group_id="O3" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB changes from baseline&gt;60 ms</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="851"/>
                    <count group_id="O3" value="1060"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF&gt;500 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="851"/>
                    <count group_id="O3" value="1060"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF&gt;480 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="851"/>
                    <count group_id="O3" value="1059"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF&gt;450 msec (n=545,838,1043)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="838"/>
                    <count group_id="O3" value="1043"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF changes from baseline&gt;30 ms</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="851"/>
                    <count group_id="O3" value="1060"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF changes from baseline&gt;60 ms</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="851"/>
                    <count group_id="O3" value="1060"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR&gt;250 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="845"/>
                    <count group_id="O3" value="1051"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 5 years.</time_frame>
      <desc>Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events fields &quot;number of deaths resulting from adverse events&quot; all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Any AIN457 150 mg</title>
          <description>safety data from patients while on AIN457 150 mg</description>
        </group>
        <group group_id="E2">
          <title>Any AIN457 300 mg</title>
          <description>safety data from patients while on AIN457 300 mg</description>
        </group>
        <group group_id="E3">
          <title>Any AIN457 Dose</title>
          <description>safety data from patients while on any dose of AIN457</description>
        </group>
        <group group_id="E4">
          <title>AIN457 150 mg - Placebo</title>
          <description>safety data from patients of corresponding randomized withdrawal group while on placebo</description>
        </group>
        <group group_id="E5">
          <title>AIN457 300 mg - Placebo</title>
          <description>safety data from patients of corresponding randomized withdrawal group while on placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="198" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Malformation venous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperandrogenism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intestinal pseudo-obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Medical device site granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tick-borne viral encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Procedural hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cranial nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Drooling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Aversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vaginal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="386" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="679" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="889" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="86" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="375" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="545"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="1113"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

